Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling

BMC Neurology

Table 3 Molecular tests with a significant (p<0.1) association with GS; sorted by OR

Test	Method	NCBI	p (FET)	nGS	pGS	nGB	pGB	OR	95% CI OR	EMT
More positive results in GS vs. GB
CALR	CNA	CALR	0.038	1/24	4.2%	0/603	0%	∞	0.64 — ∞	[9]
NTRK1	F-RNA	NTRK1	0.074	1/22	4.5%	1/563	0.2%	25	0.33 — 2100	[10]
LYL1	CNA	LYL1	0.075	1/24	4.2%	1/603	0.2%	25	0.32 — 2000	[11]
PTCH1	NGS	PTCH1	0.081	1/25	4%	1/582	0.2%	24	0.30 — 1900	[12]
IDH2	NGS	IDH2	0.080	1/27	3.7%	1/631	0.2%	23	0.30 — 1900	[13]
SHP-2	NGS	PTPN11	0.080	3/47	6.4%	21/1046	2%	3.2	0.61 — 12	[14, 15]
NF1	NGS	NF1	0.019	8/25	32%	81/587	2.3%	2.7	1.1 — 7.5	[16]
PD-L1	IHC**	CD274	0.0057	15/42	36%	152/902	17%	2.1	1.3 — 5.5	[17, 18]
PD-1	IHC	PDCD1	0.014	20/26	77%	211/408	52%	1.5	1.2 — 9.6	[19]
Fewer positive results in GS vs. GB
EGFRvIII	FFA		0.02	2/38	5.3%	143/706	20%	0.27	0.03 — 0.88
EGFRvIII	FA		0.06	1/24	4.2%	71/349	20%	0.21	0.004 — 1.1
EGFR	CNA	EGFR	0.0008	2/27	7.4%	231/623	37%	0.20	0.02 — 0.55	[20]
EGFR	NGS		0.011	0/47	0%	112/1044	11%	0	0 — 0.69
IDH1	NGS	IDH1	0.046	0/47	0%	87/1047	8.3%	0	0 — 0.92

Abbreviations: Test Common name, Method See abbreviations in Table 1; ** = using SP142 antibody, NCBI Hyperlink to NCBI GeneID, given by Official Name, p (FET) probability (p value, Fisher’s exact test), nGS Number of positive results in cases of gliosarcoma (+ve/total), pGS Percentage of positive results in cases of gliosarcoma, nGB Number of positive results in cases of glioblastoma (+ve/total), pGB Percentage of positive results in cases of glioblastoma, OR Odds ratio = pGS/pGB, 95% CI OR 95% confidence interval for OR, EMT Reference(s) supporting the role of gene/protein in epithelial-to-mesenchymal transition (EMT)

ISSN: 1471-2377